| Halaven (eribulin mesylate) / Eisai |
| Completed | 2 | 163 | Europe | Eribulin, Halaven(R) | SOLTI Breast Cancer Research Group, Eisai Inc. | Breast Cancer | 06/15 | 06/15 | | |
NCT01912963: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer |
|
|
| Terminated | 2 | 32 | US | Pertuzumab, Perjeta, Trastuzumab, Herceptin, eribulin, eribulin mesylate, Halaven | Dana-Farber Cancer Institute, Eisai Inc., Genentech, Inc. | HER2-positive Breast Cancer, Metastatic Breast Cancer | 12/16 | 12/16 | | |
| Completed | 1b/2 | 76 | Europe, RoW | Eribulin mesylate, Capecitabine | Eisai Limited | Metastatic Breast Cancer | 07/14 | 10/15 | | |
NCT01126736 / 2009-016047-19: Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 98 | Europe, US, RoW | eribulin mesylate, halichrondrin B analog; Alimta, pemetrexed, Eribulin mesylate (eribulin; E7389) | Eisai Inc., Quintiles, Inc. | Non Small Cell Lung Cancer | 12/12 | 03/15 | | |
NCT01744340: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer |
|
|
| Completed | 1/2 | 23 | US | Head and neck, Colon- Closed as of May 2014 | howard safran, Fatima Memorial Hospital, Montefiore Medical Center, Rhode Island Hospital, The Miriam Hospital | Head and Neck Cancer, Colon Cancer | 03/15 | 07/15 | | |
NCT01126749: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer |
|
|
| Terminated | 1/2 | 92 | Europe, US, RoW | Gemcitabine, E7389, Eribulin Mesylate, Cisplatin | Eisai Inc., PharmaBio Development Inc. | Bladder Cancer | 05/15 | 07/16 | | |
NCT01596751: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 67 | US | PLX3397, Eribulin, Halaven, E7389 | Hope Rugo, MD, Susan G. Komen Breast Cancer Foundation, Plexxikon | Metastatic Breast Cancer | 07/17 | 07/19 | | |
NCT01554371: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies |
|
|
| Completed | 1/2 | 44 | US | Eribulin, Halaven, E7389, ER-086526, Cyclophosphamide, Cytoxan | University of California, San Francisco, Eisai Inc. | Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy | 12/19 | 12/19 | | |
